China Direct-Acting HCV Drug Race Rapidly Gathering Pace
After the recent approval of its first all-oral hepatitis C regimen, the China FDA is striving to approve within a year more direct-acting antiviral (DAA) therapies to treat all genotypes of the disease, setting the stage for both multinational and domestic pharma firms to compete in the world’s largest HCV drug market.
You may also be interested in...
Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
In signs of a strategy shift, Gilead Sciences appears to be independently pursuing opportunities in China's rapidly growing hepatitis market by appointing a top market access executive.